| Basics |
Wave Life Sciences Ltd. Ordinary Shares
WAVE Life Sciences Ltd is a preclinical therapeutics developer in Singapore. Its pipeline of drugs is intended to cure rare genetic disorders such as Huntington, duchenne muscular dystrophy (DMD) and inflammatory bowel disease.
|
| IPO Date: |
November 11, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.25B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.47 | 3.32%
|
| Avg Daily Range (30 D): |
$0.18 | 2.41%
|
| Avg Daily Range (90 D): |
$0.22 | 2.87%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.48M |
| Avg Daily Volume (30 D): |
1.87M |
| Avg Daily Volume (90 D): |
1.64M |
| Trade Size |
| Avg Trade Size (Sh.): |
104 |
| Avg Trade Size (Sh.) (30 D): |
101 |
| Avg Trade Size (Sh.) (90 D): |
93 |
| Institutional Trades |
| Total Inst.Trades: |
1,122 |
| Avg Inst. Trade: |
$1.47M |
| Avg Inst. Trade (30 D): |
$1.85M |
| Avg Inst. Trade (90 D): |
$1.8M |
| Avg Inst. Trade Volume: |
.14M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.69M |
| Avg Closing Trade (30 D): |
$1.5M |
| Avg Closing Trade (90 D): |
$1.6M |
| Avg Closing Volume: |
176.49K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-.8
|
$-.31
|
$-.29
|
|
Diluted EPS
|
$-.8
|
$-.31
|
$-.29
|
|
Revenue
|
$ 93.95M
|
$ 8.7M
|
$ 9.18M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -129.87M
|
$ -50.47M
|
$ -46.88M
|
|
Operating Income / Loss
|
$ -143.51M
|
$ -52.76M
|
$ -49.8M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 54.46M
|
$ -34.63M
|
$ -59.05M
|
|
PE Ratio
|
|
|
|
|
|
|
